Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $60.08

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $60.0833.

A number of research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Cantor Fitzgerald lowered their price target on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday, December 2nd. HC Wainwright dropped their price objective on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Barclays decreased their target price on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Finally, Piper Sandler dropped their price target on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $32.98, for a total transaction of $109,922.34. Following the completion of the transaction, the insider directly owned 84,974 shares in the company, valued at $2,802,442.52. The trade was a 3.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas Diraimondo sold 2,505 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $34,393.65. Following the completion of the sale, the insider directly owned 124,425 shares in the company, valued at approximately $1,708,355.25. The trade was a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 25,699 shares of company stock worth $471,235 in the last three months. Company insiders own 8.10% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC increased its holdings in shares of Janux Therapeutics by 230.0% during the 2nd quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock worth $4,379,000 after buying an additional 132,121 shares during the last quarter. Quinn Opportunity Partners LLC increased its stake in Janux Therapeutics by 15.4% during the second quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock worth $1,384,000 after acquiring an additional 8,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Janux Therapeutics by 15.5% in the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after purchasing an additional 121,403 shares during the period. AlphaQuest LLC lifted its stake in shares of Janux Therapeutics by 3,658.9% in the 2nd quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock valued at $224,000 after purchasing an additional 9,440 shares in the last quarter. Finally, Capital Fund Management S.A. acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at about $757,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $13.07 on Friday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $41.56. The stock has a fifty day moving average price of $14.73 and a two-hundred day moving average price of $21.87. The stock has a market capitalization of $786.16 million, a price-to-earnings ratio of -7.78 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. On average, analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.